On April 26, 2023 I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, reported that a poster featuring the latest clinical data of uliledlimab, the Company’s proprietary and highly differentiated CD73 antibody, in combination with PD-1 therapy in non-small-cell lung cancer (NSCLC), will be presented at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 2-6 in Chicago, Illinois (Press release, I-Mab Biopharma, APR 26, 2023, View Source [SID1234630567]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Abstract Title:
Uliledlimab and Toripalimab Combination Therapy in Treatment Naïve Advanced
NSCLC: Phase 1b/2 Clinical Trial Results Using CD73 as a Potential Predictive Biomarker
Abstract Number:
2570
Presenting Author:
Prof. Qing Zhou, Guangdong Provincial People’s Hospital
Session:
Developmental Therapeutics – Immunotherapy
Location:
Hall A, McCormick Place Convention Center, Chicago, Illinois
Presentation Date/Time:
June 3, 2023, 8:00 am – 11:00 am E.T.
About Uliledlimab
Uliledlimab (also known as TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine, in turn, binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in the tumor microenvironment. Uliledlimab is expected to offer clinical benefits by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties, as evident in preclinical studies.